From: MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
Patients, number | 161 | Â | Â |
---|---|---|---|
Male/female, number | 40/121 | Â | Â |
Age, years | 57.4 ± 12.2 | (median 58) | n = 161 |
Onset age, years | 53.0 ± 12.4 | (median 54) | n = 161 |
Disease duration, years | 4.4 ± 6.9 | (median 1.4) | n = 161 |
Methotrexate used, number of patients (%) | 161 (100) |  | n = 161 |
Baseline methotrexate dose, mg/wk | 4.3 ± 0.9 | (median 4) | n = 161 |
Prednisolone used, number (%) | 38 (23.6) |  | n = 38 |
Baseline prednisolone dose, mg/day | 5.0 ± 3.2 |  | n = 38 |
Baseline prednisolone dose, mg/day | 1.2 ± 2.6 | (median 0) | n = 161 |
Conventional disease-modifying anti-rheumatic drugs used, number of patients (%) | 73 (45.3) |  | n = 161 |
Stage 1 | 73 | 45.3Â % | Â |
Stage 2 | 42 | 26.1Â % | Â |
Stage 3 | 28 | 17.4Â % | Â |
Stage 4 | 18 | 11.2Â % | Â |
Class I | 78 | 48.4Â % | Â |
Class II | 76 | 47.2Â % | Â |
Class III | 7 | 4.3Â % | Â |
Class IV | 0 | 0.0Â % | Â |
C-reactive protein, mg/dl | 2.6 ± 3.0 | (median 1.5) | n = 161 |
Erythrocyte sedimentation rate, mm/h | 55.1 ± 35.1 | (median 48) | n = 161 |
Tender joint count | 7.1 ± 5.7 | (median 6) | n = 161 |
Swollen joint count | 7.5 ± 5.4 | (median 7) | n = 161 |
Disease activity score in 28 joints-C-reactive protein (4) | 4.8 ± 1.1 | (median 4.6) | n = 129 |
Disease activity score in 28 joints-erythrocyte sedimentation rate (4) | 5.5 ± 1.2 | (median 5.5) | n = 129 |
Disease activity score in 28 joints-C-reactive protein (3) | 4.5 ± 1.0 | (median 4.3) | n = 161 |
Disease activity score in 28 joints-erythrocyte sedimentation rate (3) | 5.2 ± 1.1 | (median 5.2) | n = 161 |
Visual analog scale, mm | 52.4 ± 28.0 | (median 51) | n = 129 |
Matrix metalloproteinase-3, ng/ml | 241.9 ± 304.2 | (median 133) | n = 157 |
Rheumatoid factor | 119.2 ± 226.5 | (median 45.3) | n = 157 |
Morning stiffness, minutes | 165.6 ± 362.6 | (median 35) | n = 158 |
Grip strength, (L+ R)/2 mmHg | 176.8 ± 66.7 | (median 171) | n = 157 |
Modified health assessment questionnaire | 0.543 ± 0.469 | (median 0.500) | n = 130 |
Baseline van der Heijde modified total Sharp score | 18.6 ± 33.2 | (median 4.0) | n = 161 |
Baseline van der Heijde modified total Sharp score, progression, –1 to 0 years | 7.9 ± 19.0 | (median 3.0) | n = 161 |